Get Connected:

 

FDA OKs Neurostimulation Device for Opioid Withdrawal

DyAnsys Inc. announced that its auricular neurostimulation device, Drug Relief, received clearance from the FDA. 
Published Online: Jun 13,2018
Cecilia Pessoa Gingerich
DyAnsys Inc. announced that its auricular neurostimulation device, Drug Relief, received clearance from the FDA. The device is a non-narcotic option to aid in alleviating opioid withdrawal symptoms.

"This device offers hope to those who are suffering from opioid addiction," said DyAnsys Chief Executive Officer Srini Nageshwar, a graduate of the Institute of Technology Madras.

Drug Relief sends electrical pulses through fine needles inserted in the ear over the course of 120 hours. The device stimulates the percutaneous electrical nerve field to reduce symptoms including anxiety, agitation, depression, nausea, and opiate cravings, and increase comfort and mobility for the patient.

Click to continue reading on MD Magazine.